title: [Influence of Eqb 761 on the function of the retina in children and adolescent with long lasting diabetes mellitus--preliminary report].
abstract: OBJECTIVE
  Early detection of patological function of the retina, before anatomical changes, plays very important role in monitoring of visual complications in patients with diabetes mellitus. The aim of the study was the evaluation of anatomical and functional changes in visual organ in children and adolescents with long lasting diabetes mellitus type 1 and taking Egb 761 (Tanakan Beaufour Ipsen) as an adjuvant.
  
  
  METHODS
  Group consists of 15 patients, age between 11 and 19 years, with diabetes mellitus lasting 6-12 years. All patients had full ophthalmologic examination and color vision tests (Panel D 15 saturated and desaturated). The examination was done 3 times, every 3 months. Egb 761 was given: 1 tablet - 3 times a day, during 3 months.
  
  
  RESULTS
  No diabetic retinopathy was found. The results of color vision test were better after therapy (25% of pathological results) and 3 months later (only 4 % of patients).
  
  
  CONCLUSIONS
  1. Egb 761 seems to be good adjuvant in patient with long lasting diabetes mellitus. 2. Color vision tests are sensitive tests of the retinal function and are easy to perform.
authors.affiliation: Z Katedry i Kliniki Okulistyki Akademii Medycznej w Poznaniu.
authors.forename: Jadwiga
authors.initials: J
authors.lastname: Bernardczyk-Meller
authors.forename: Joanna
authors.initials: J
authors.lastname: Siwiec-Prościńska
authors.forename: Witold
authors.initials: W
authors.lastname: Stankiewicz
authors.forename: Piotr
authors.initials: P
authors.lastname: Fichna
authors.forename: Krystyna
authors.initials: K
authors.lastname: Pecold
authors.forename: Eugeniusz
authors.initials: E
authors.lastname: Korman
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003118:Color Perception / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003930:Diabetic Retinopathy / Q000175:diagnosis* / Q000209:etiology*; D004334:Drug Administration Schedule; D020441:Ginkgo biloba; D006801:Humans; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D012160:Retina / Q000187:drug effects* / Q000503:physiopathology; D000096983:Ginkgo Extract
chemical_list: D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract